Bragg Financial Advisors Inc increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.1% during the first quarter, Holdings Channel reports. The fund owned 265,442 shares of the biopharmaceutical company’s stock after acquiring an additional 10,368 shares during the quarter. Bragg Financial Advisors Inc’s holdings in Pfizer were worth $6,726,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in the business. Clarity Asset Management Inc. acquired a new position in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC lifted its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the period. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter worth $27,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter worth $28,000. Finally, North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter worth $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Pfizer Stock Up 1.3%
Shares of NYSE:PFE opened at $25.7060 on Friday. The stock has a market cap of $146.15 billion, a price-to-earnings ratio of 13.67, a PEG ratio of 0.90 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The business’s 50 day moving average is $24.68 and its 200 day moving average is $24.42.
Pfizer Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s payout ratio is currently 91.49%.
Analyst Upgrades and Downgrades
PFE has been the subject of several recent analyst reports. Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Wolfe Research raised their target price on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research note on Wednesday, April 30th. Finally, The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.12.
Get Our Latest Stock Analysis on PFE
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
- Five stocks we like better than Pfizer
- About the Markup Calculator
- Shopify’s Risk-Reward Profile Is Suddenly Red Hot
- A Deeper Look at Bid-Ask Spreads
- 3 Robotics Stocks at the Heart of the Robotics Revolution
- What Is WallStreetBets and What Stocks Are They Targeting?
- Tilray’s High Hopes: The Catalyst Driving Cannabis Stocks
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.